Home › Research › Risk factors
Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration
Teemu Niiranen, Renate B. Schnabel, Aletta Elisabeth Schutte, Yitschak Biton, Giuseppe Boriani, Claire Mary Buckley, Alan C. Cameron, Albertino Antonio Moura Damasceno et al.. Circulation, 2025-03-24
Topic: Risk, prevention and care in population studies
Plain-language summary
Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF-SCREEN International Collaboration to summarize existing evidence and knowledge gaps on links between hypertension, AF, and their cardiovascular sequelae; simultaneous screening for hypertension and AF; and the prevention of AF through antihypertensive therapy. Hypertension and AF are inextricably connected. Both are easily diagnosed, often silent, and frequently treated inadequately. Together, they additively increase the risk of ischemic stroke, heart failure, and many types of dementia, resulting in greater all-cause mortality, considerable disease burden, and increased health care expenditures. Automated upper arm cuff blood pressure devices with implemented technology can be used to simultaneously detect both hypertension and AF. However, positive screening for AF with an oscillometric blood pressure monitor still requires ECG confirmation. The current evidence suggests that high-risk individuals aged ≥65 years or with treatment-resistant hypertension could benefit from AF screening. Since antihypertensive therapy effectively lowers AF risk, particularly in individuals with left ventricular dysfunction, hypertension should be the key target for AF prediction and prevention rather than merely a comorbidity of AF. Nevertheless, several important gaps in knowledge need to be filled over the next years, including the ideal method and selection of patients for simultaneous screening of hypertension and AF and the optimal antihypertensive drug class and blood pressure targets for AF prevention.
What this study adds
Evidence grade: Low
This review from the AF-SCREEN International Collaboration describes how hypertension and atrial fibrillation are connected and together additively increase the risk of ischemic stroke, heart failure, and many types of dementia. It suggests that high-risk individuals aged 65 or older or with treatment-resistant hypertension could benefit from atrial fibrillation screening, and that hypertension should be a key target for prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Niiranen, T., Schnabel, R. B., Schutte, A. E., Biton, Y., Boriani, G., Buckley, C. M., et al. (2025). Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration. Circulation. https://doi.org/10.1161/circulationaha.124.071047
Vancouver
Niiranen T, Schnabel RB, Schutte AE, Biton Y, Boriani G, Buckley CM, et al. Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration. Circulation. 2025. doi:10.1161/circulationaha.124.071047. PMID: 40127157.
BibTeX
@article{niiranen2025-40127157,
author = {Niiranen, Teemu and Schnabel, Renate B. and Schutte, Aletta Elisabeth and Biton, Yitschak and Boriani, Giuseppe and Buckley, Claire Mary and Cameron, Alan C. and Damasceno, Albertino Antonio Moura and others},
title = {{Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration}},
journal = {Circulation},
year = {2025},
doi = {10.1161/circulationaha.124.071047},
pmid = {40127157},
url = {https://doi.org/10.1161/circulationaha.124.071047}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The current evidence suggests that high-risk individuals aged ≥65 years or with treatment-resistant hypertension could benefit from AF screening.
Why it matters
This review from the AF-SCREEN International Collaboration describes how hypertension and atrial fibrillation are connected and together additively increase the risk of ischemic stroke, heart failure, and many types of dementia. It suggests that high-risk individuals aged 65 or older or with treatment-resistant hypertension could benefit from atrial fibrillation screening, and that hypertension should be a key target for prevention.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Circulation) |
| Journal's citation record | 4 / 4 | Circulation: journal h-index 848 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 16.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Ben Freedman: h-index 62 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 52 institution(s) in 18 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40127157) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Risk factors from nearby years
Also in Risk factors
383 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.